Corrections:

Yangyang Xu¹, Lin Zhang², Yuzhen Wei^1,3, Xin Zhang¹, Ran Xu¹, Mingzhi Han¹, Bing Huang¹, Anjing Chen¹, Wenjie Li¹, Qing Zhang¹, Gang Li¹, Jian Wang^1,4, Peng Zhao¹ and Xingang Li¹

¹ Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Jinan 250012, China
² Institute of Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan 250012, China
³ Department of Neurosurgery, Jining No.1 People’s Hospital, Jining 272011, China
⁴ Department of Biomedicine, University of Bergen, 5009 Bergen, Norway

Published: July 06, 2021

Copyright: © 2021 Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors during the assembly of Figure 5B, incorrect images were placed in row 1, panel 4 and row 2, panel 4. The corrected Figure 5B, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:23401–23413. DOI: https://doi.org/10.18632/oncotarget.15581.

Figure 5: Treatment with FAK inhibitor attenuates U87 and U251 cell migration and invasion. (B) Representative images and quantification (cell number/field) of transwell migration assays for parental U87 and U251 cells treated with TAE226 (5 μM) under normoxic and hypoxic conditions (Scale bars, 50 μm).